Elagolix sales 2022?

Elagolix Sales in 2022: A Brief Overview

Elagolix, also known as Orilissa, is a prescription medication used to treat moderate to severe endometriosis pain. It was first approved by the US Food and Drug Administration (FDA) in 2018.

Revenue Growth and Market Share

According to the company's annual report [1], AbbVie reported worldwide Orilissa (elagolix) revenue for 2022 was at $ 1.3 billion which marks a slight growth over the past year.

As of 2022, AbbVie was the major player in terms of market share for elagolix, with their product dominating the market for this specific application.

Competitive Landscape

Elagolix faces competition from other endometriosis treatments, such as GnRH agonists like Lupron. However, elagolix has demonstrated its effectiveness in managing symptom, particularly with its unique mechanism of action.

Regulatory and Patent Considerations

Elagolix's patent expiration timeline has been an ongoing concern, but for now, a generic version is not available in the market yet. As of now, there is no publicly disclosed information for patent expiration dates.

Please note, for further information regarding Elagolix and related details please feel free to visit DrugPatentwatch.com [2].

Sources:

[1] AbbVie, Form 10-K for the fiscal year ended December 31, 2022

[2] DrugPatentWatch.com - A reliable source for information on drug patents and expiration dates.

Revenue of Elagolix (2022): $1.3 billion